Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Express Scripts
Queensland Health
Farmers Insurance
Daiichi Sankyo

Generated: September 19, 2017

Patent: ► Subscribe

Summary for Patent: ► Subscribe

Title:Treatment of ophthalmic conditions
Abstract: Ophthalmic conditions such as presbyopia, myopia, and astigmatism can be corrected by the use of a molding contact lens in combination with a pharmaceutical composition suitable for delivery to the eye. The molding contact lenses are preferably commercially available and are not specifically designed for orthokeratology. The agents in the pharmaceutical compositions such as hyaluronase allow the cornea of the eye to be molded in order to correct the refractive error of the eye. The contact lenses and the pharmaceutical composition induce a change in the radius of curvature of the anterior surface of the cornea, thereby correcting the refractive error of the eye. One advantage of the inventive technique is that the patient with his or her own individual visual needs guides the treatment until the patient near and far visual needs are met. The present invention also provides for kits, which contain molding contact lenses, pharmaceutical composition suitable for delivery to the eye, and instructions, useful in the inventive system.
Inventor(s): Osio Sancho; Alberto (Mexico, D.F., MX)
Assignee: Osio Corporation (Coronado, CA)
Application Number:15/004,246
Patent Claim Types:
see list of patent claims
Use; Dosage form; Composition;

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Inventors Patent Expiration Status Orphan Source
Advance Biofactures
VIAL1019950011965-06-04► Subscribe Osio Corporation (Coronado, CA) Osio Sancho; Alberto (Mexico, D.F., MX) ► SubscribeRXsearch
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Summary for Patent: ► Subscribe

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Mexico011987Dec 19, 2003

International Patent Family for Patent: ► Subscribe

Country Document Number Publication Date
Australia2004308326Feb 10, 2011
Australia2004308326Jul 14, 2005
BrazilPI0417785Mar 20, 2007
Canada2549333Aug 05, 2014
Canada2549333Jul 14, 2005
China100591354Feb 24, 2010
China1901882Jan 24, 2007
Costa Rica8453Dec 07, 2006
EcuadorSP066657Nov 24, 2006
Egypt24420May 25, 2009
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
US Department of Justice
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.